The European Medicines Agency's recommendation to extend Wegovy marketing authorization to an oral semaglutide formulation represents more than a simple delivery switch; it targets the core friction points of injectable GLP-1 therapies that have constrained population-level impact since their 2021-2023 rollout. While the MedicalXpress report correctly notes US prescription surges exceeding 200,000 weekly and EU adult-only labeling, it underplays how needle aversion and cold-chain logistics have skewed uptake toward higher-income, urban cohorts. Peer-reviewed evidence from the STEP 1 RCT (n=1961, double-blind, Novo Nordisk-funded) demonstrated 14.9% mean weight loss at 68 weeks versus 2.4% placebo, yet observational follow-up studies reveal 40-60% discontinuation by 12 months largely due to injection burden. Oral semaglutide, already validated in PIONEER trials (RCTs totaling >9000 participants across diabetes indications), offers 3-5% absolute bioavailability with strict fasting requirements, a limitation the source omits. This positions the pill as a potential adherence lever for chronic disease models, echoing statin-era shifts where oral options doubled persistence rates in large cohort analyses. Pricing variability across EU member states and the absence of adolescent data further risk entrenching inequities, a gap the coverage does not interrogate. Synthesizing these threads, the approval accelerates obesity's reframing as a treatable chronic condition, but only if post-marketing surveillance addresses gastrointestinal tolerability and food-effect variability that reduced efficacy in real-world oral GLP-1 cohorts.